About HistoTox
HistoTox is a Healthcare company based in Boulder (United States) founded in 2003, and was acquired by Inotiv in April 2021. CRO offers histopathology and image analysis services. HistoTox offers products and services including Toxicology Services, Research Models, and Teklad Diets. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Pathology & Imaging. Its legal entity is Inotiv, Inc. Its competitors include Asterand Bioscience, StageBio and Numira; 2 of its 3 listed competitors have raised funding.
Company details
HistoTox was founded in 2003 and is based in Boulder, United States. As a contract research organization in the life sciences sector, histopathology services are delivered alongside image analysis capabilities. These offerings support pharmaceutical and biotechnology clients in drug discovery and development processes. Operations emphasize precise tissue evaluation and digital imaging for research applications across preclinical studies.
- Headquarters Boulder, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website histotoxlabs.com
- Social LinkedIn Facebook
- Acquired by Inotiv (Apr 2021)
- Legal Name Inotiv, Inc.
Products & Services of HistoTox
HistoTox offers a comprehensive portfolio of products and services, including Toxicology Services, Research Models, and Teklad Diets.
Evaluates safety of drugs and chemicals through studies
Provides models for therapeutic area research and testing
Offers specialized diets and bedding for laboratory animals
Investors in HistoTox
HistoTox has secured backing from 1 investor. Prominent investors backing the company include Inotiv Co.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Clinical development and regulatory services are provided by Inotiv. | 1974 | inotivco.com | Lafayette, United States |
Investor details for HistoTox
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of HistoTox
2 dated milestones of HistoTox across 18 years, from founding to its latest funding, stage changes and deals.
- Founded HistoTox is founded.
- Exit Acquired by Inotiv.
Competitors of HistoTox
HistoTox has 3 listed competitors in our database, 2 of them funded. They include Asterand Bioscience, StageBio and Numira.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| asterandbio.com | 2000 | Detroit, United States | $7.11M | Human tissue solutions for drug discovery research are supplied globally. | ||
| stagebio.com | 2001 | Mount Jackson, United States | Preclinical pathology services are provided for research and development needs. | |||
| numira.com | 2005 | Salt Lake, United States | $5.78M | Numira is a specialty preclinical CRO specializing in microCT imaging, image analysis, histology, and 3D cancer cell profiling. |
Detailed competitors of HistoTox
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as HistoTox (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Histotox
Complete news archive for HistoTox
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HistoTox
HistoTox was founded in 2003.
HistoTox is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
HistoTox was founded in 2003 and is based in Boulder, United States. As a contract research organization in the life sciences sector, histopathology services are delivered alongside image analysis capabilities. These offerings support pharmaceutical and biotechnology clients in drug discovery and development processes. Operations emphasize precise tissue evaluation and digital imaging for research applications across preclinical studies.
HistoTox's top competitors include Asterand Bioscience, StageBio and Numira.
HistoTox offers Toxicology Services, Research Models, and Teklad Diets.
HistoTox has 1 investor. Key investors include Inotiv Co.
HistoTox operates through Inotiv, Inc..
Yes. HistoTox was acquired by Inotiv in April 2021.